IGHE and anaphylaxis: There have been many reports of off-label uses of omalizumab in diseases where IgE might have a pathogenic role, such as allergic rhinitis, ABPA, anaphylaxis, angioedema, non-atopic asthma, atopic dermatitis, EGPA, and CRS (142).